+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs Used for Treating Primary Aldosteronism Market - Global Forecast 2026-2032- Product Image
Drugs Used for Treating Primary Aldosteronism Market - Global Forecast 2026-2032- Product Image
Sale

Drugs Used for Treating Primary Aldosteronism Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6081445
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drugs Used for Treating Primary Aldosteronism Market is projected to reach USD 284.90 Million in 2026. It is expected to continue growing at a CAGR of 7.21%, reaching USD 432.32 Million by 2032.

Primary Aldosteronism Treatment: Executive Summary

Drugs used to treat primary aldosteronism address excess aldosterone, a hormonal disorder associated with hypertension, potassium abnormalities, cardiovascular complications, and kidney damage. Pharmacological management is central for patients who are not candidates for adrenal surgery, those with bilateral disease, and individuals requiring treatment while diagnostic evaluation is completed. The therapeutic approach depends on biochemical confirmation, subtype assessment, comorbidities, renal function, potassium status, and access to specialist care.

From Blood-Pressure Control to Aldosterone-Directed Care

Treatment practice is shifting from treating resistant hypertension alone toward identifying and directly managing autonomous aldosterone production. This change is supported by broader screening of patients with difficult-to-control blood pressure, improved use of confirmatory testing, and greater recognition that aldosterone-related risk can persist even when blood pressure appears controlled. Mineralocorticoid receptor antagonists remain the principal drug-based approach, while potassium monitoring, renal assessment, medication reconciliation, and long-term follow-up are essential to safe use. Diagnostic capacity and clinician familiarity continue to influence how consistently these therapies are initiated and optimized.

Artificial Intelligence Strengthens Detection and Treatment Monitoring

Artificial intelligence can support primary aldosteronism care by identifying patients whose clinical records show patterns such as resistant hypertension, unexplained hypokalemia, early-onset hypertension, or repeated antihypertensive treatment changes. It may also assist with interpretation of laboratory trends, prioritization of confirmatory testing, and monitoring for hyperkalemia or renal-function deterioration after therapy begins. These applications remain dependent on high-quality data, transparent validation, clinician oversight, and safeguards against biased underdiagnosis. AI should complement endocrine and hypertension expertise rather than replace biochemical confirmation or individualized prescribing.

Regional Differences Reflect Diagnostic Capacity and Access

In North America, established hypertension services and growing awareness of secondary hypertension support broader case finding, although fragmented care and medication-monitoring requirements can delay treatment. Europe combines strong specialist networks with variation in screening pathways and reimbursement across countries. Asia-Pacific includes advanced health systems with expanding endocrine expertise alongside settings where confirmatory testing and long-term follow-up are less available. Latin America faces uneven access to specialist evaluation, laboratory services, and newer treatment options. The Middle East is seeing increasing attention to cardiometabolic disease and specialized hypertension care, while Africa remains highly diverse, with access shaped by laboratory capacity, medicine availability, and the distribution of trained clinicians.

Economic and Policy Groups Shape Care Pathways

Across ASEAN, differences in health-system resources and specialist availability make standardized screening and affordable medicine access important priorities. BRICS countries span substantial variation in diagnostic infrastructure, public procurement, and continuity of chronic-care services. European Union systems benefit from shared clinical knowledge while retaining country-specific reimbursement and referral processes. G7 members generally have greater access to specialist assessment and laboratory monitoring, but still face underdiagnosis and care fragmentation. GCC countries are positioned to expand endocrine and hypertension services through concentrated health-system investment, whereas NATO members show varied national approaches despite extensive clinical collaboration and shared attention to cardiovascular risk.

Country-Level Priorities for Primary Aldosteronism Management

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally have established pathways for hypertension management, but diagnostic referral and treatment intensity vary by region and health system. Brazil, China, India, Mexico, and Russia must address differences between major urban centers and underserved areas, including access to aldosterone testing, adrenal imaging, specialist review, and potassium surveillance. Across all listed countries, practical priorities include improving awareness of secondary hypertension, reducing delays between suspicion and confirmation, and supporting consistent follow-up for patients receiving mineralocorticoid receptor antagonists.

Priorities for Leaders: Find Cases Earlier and Monitor More Reliably

Industry and health-system leaders should strengthen protocols for screening patients with resistant or unusually severe hypertension, align laboratory pathways with medication-management requirements, and expand education for primary-care, cardiology, nephrology, and endocrinology teams. Treatment programs should pair prescribing with structured potassium and renal-function monitoring, clear dose-adjustment guidance, and patient education on symptoms and interacting medicines. Access strategies should account for affordability, geographic distribution of specialists, and continuity of care. Digital tools, including carefully validated clinical decision support, can help identify missed cases and prompt follow-up while preserving clinician accountability and patient privacy.

Methodology: Evidence-Led Synthesis of Treatment and Care Dynamics

This executive summary uses the defined market scope of drugs used for treating primary aldosteronism and synthesizes established clinical, diagnostic, health-system, and implementation considerations. The assessment is organized across treatment evolution, artificial-intelligence applications, required regions, economic and policy groups, and specified countries. It emphasizes verified clinical principles and observable care-system differences while excluding market estimates, market sizing, market shares, forecasts, and company-specific analysis. Country and regional observations are framed as broad access and practice considerations rather than quantitative rankings.

Conclusion: Better Recognition Enables More Targeted Treatment

Primary aldosteronism management is increasingly centered on recognizing aldosterone excess as a distinct and treatable driver of hypertension and cardiovascular risk. Drug therapy remains essential for many patients, particularly when surgery is unsuitable or disease is bilateral, but its value depends on accurate diagnosis and disciplined monitoring. Progress will require coordinated screening, stronger referral pathways, reliable laboratory capacity, equitable medicine access, and responsible use of digital and AI-enabled tools across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Drugs Used for Treating Primary Aldosteronism Market, by Molecule
7.1. Introduction
7.2. Eplerenone
7.3. Finerenone
7.4. Spironolactone
8. Drugs Used for Treating Primary Aldosteronism Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Drugs Used for Treating Primary Aldosteronism Market, by Line Of Therapy
9.1. Introduction
9.2. First Line
9.3. Second Line
10. Drugs Used for Treating Primary Aldosteronism Market, by Formulation
10.1. Introduction
10.2. Extended Release
10.2.1. Capsule
10.2.2. Tablet
10.3. Immediate Release
10.3.1. Suspension
10.3.2. Tablet
11. Drugs Used for Treating Primary Aldosteronism Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
11.3.1. Chain Pharmacy
11.3.2. Independent Pharmacy
12. Drugs Used for Treating Primary Aldosteronism Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Drugs Used for Treating Primary Aldosteronism Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Drugs Used for Treating Primary Aldosteronism Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Aurobindo Pharma Limited
16.2. Cipla Limited
16.3. Dr. Reddy's Laboratories Ltd.
16.4. Glenmark Pharmaceuticals Limited
16.5. Lupin Limited
16.6. Novartis AG
16.7. Pfizer Inc.
16.8. Sun Pharmaceutical Industries Ltd.
16.9. Teva Pharmaceutical Industries Ltd.
16.10. Viatris Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Drugs Used for Treating Primary Aldosteronism Market, Years Considered for the Study
FIGURE 2. Global Drugs Used for Treating Primary Aldosteronism Market, Research Design
FIGURE 3. Global Drugs Used for Treating Primary Aldosteronism Market, Research Framework
FIGURE 4. Global Drugs Used for Treating Primary Aldosteronism Market, Data Triangulation
FIGURE 5. Global Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2025 vs 2032 (%)
FIGURE 7. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 11. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 13. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Drugs Used for Treating Primary Aldosteronism Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Drugs Used for Treating Primary Aldosteronism Market Segmentation & Coverage
TABLE 2. Global Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 3. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 4. Global Eplerenone Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Eplerenone Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Eplerenone Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Finerenone Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Finerenone Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Finerenone Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Spironolactone Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Spironolactone Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Spironolactone Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 14. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 21. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 28. Global Extended Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Extended Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Extended Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Immediate Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Immediate Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Immediate Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Suspension Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Suspension Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Suspension Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 47. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Chain Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Chain Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Chain Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Independent Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Independent Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Independent Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 69. North America Drugs Used for Treating Primary Aldosteronism Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. North America Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 71. North America Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 72. North America Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 73. North America Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 74. North America Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 75. North America Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 76. North America Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. North America Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 78. Latin America Drugs Used for Treating Primary Aldosteronism Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Latin America Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 80. Latin America Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 81. Latin America Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 82. Latin America Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 83. Latin America Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 84. Latin America Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 85. Latin America Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. Latin America Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 87. Europe Drugs Used for Treating Primary Aldosteronism Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Europe Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 89. Europe Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 90. Europe Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 91. Europe Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 92. Europe Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 93. Europe Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 94. Europe Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. Europe Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 96. Middle East Drugs Used for Treating Primary Aldosteronism Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Middle East Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 98. Middle East Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 99. Middle East Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 100. Middle East Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 101. Middle East Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 102. Middle East Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 103. Middle East Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Middle East Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 105. Africa Drugs Used for Treating Primary Aldosteronism Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Africa Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 107. Africa Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 108. Africa Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 109. Africa Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 110. Africa Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 111. Africa Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 112. Africa Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. Africa Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 114. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. ASEAN Drugs Used for Treating Primary Aldosteronism Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. ASEAN Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 117. ASEAN Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 118. ASEAN Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 119. ASEAN Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 120. ASEAN Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 121. ASEAN Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 122. ASEAN Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. ASEAN Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 124. GCC Drugs Used for Treating Primary Aldosteronism Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. GCC Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 126. GCC Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 127. GCC Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 128. GCC Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 129. GCC Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 130. GCC Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 131. GCC Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. GCC Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 133. European Union Drugs Used for Treating Primary Aldosteronism Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. European Union Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 135. European Union Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 136. European Union Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 137. European Union Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 138. European Union Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 139. European Union Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 140. European Union Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. European Union Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 142. BRICS Drugs Used for Treating Primary Aldosteronism Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. BRICS Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 144. BRICS Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 145. BRICS Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 146. BRICS Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 147. BRICS Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 148. BRICS Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 149. BRICS Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. BRICS Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 151. G7 Drugs Used for Treating Primary Aldosteronism Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. G7 Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 153. G7 Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 154. G7 Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 155. G7 Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 156. G7 Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 157. G7 Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 158. G7 Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. G7 Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 160. NATO Drugs Used for Treating Primary Aldosteronism Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. NATO Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 162. NATO Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 163. NATO Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 164. NATO Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 165. NATO Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 166. NATO Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 167. NATO Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. NATO Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 169. Global Drugs Used for Treating Primary Aldosteronism Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. United States Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 171. United States Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 172. United States Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 173. United States Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 174. United States Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 175. United States Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 176. United States Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 177. United States Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. United States Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 179. Canada Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 180. Canada Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 181. Canada Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 182. Canada Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 183. Canada Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 184. Canada Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 185. Canada Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 186. Canada Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. Canada Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 188. Mexico Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 189. Mexico Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 190. Mexico Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. Mexico Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 192. Mexico Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 193. Mexico Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 194. Mexico Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 195. Mexico Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Mexico Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 197. Brazil Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 198. Brazil Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 199. Brazil Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 200. Brazil Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 201. Brazil Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 202. Brazil Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 203. Brazil Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 204. Brazil Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Brazil Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 206. United Kingdom Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 207. United Kingdom Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 208. United Kingdom Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 209. United Kingdom Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 210. United Kingdom Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 211. United Kingdom Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 212. United Kingdom Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 213. United Kingdom Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. United Kingdom Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 215. Germany Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 216. Germany Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 217. Germany Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 218. Germany Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 219. Germany Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 220. Germany Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 221. Germany Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 222. Germany Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. Germany Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 224. France Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 225. France Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 226. France Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 227. France Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 228. France Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 229. France Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 230. France Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 231. France Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. France Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 233. Russia Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 234. Russia Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 235. Russia Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 236. Russia Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 237. Russia Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 238. Russia Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 239. Russia Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 240. Russia Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. Russia Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 242. Italy Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 243. Italy Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 244. Italy Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 245. Italy Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 246. Italy Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 247. Italy Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 248. Italy Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 249. Italy Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. Italy Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 251. Spain Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 252. Spain Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 253. Spain Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 254. Spain Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 255. Spain Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 256. Spain Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 257. Spain Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 258. Spain Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. Spain Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 260. China Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 261. China Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 262. China Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 263. China Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 264. China Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 265. China Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 266. China Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 267. China Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. China Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 269. India Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 270. India Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 271. India Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 272. India Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 273. India Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 274. India Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 275. India Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 276. India Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. India Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 278. Japan Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 279. Japan Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 280. Japan Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 281. Japan Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 282. Japan Drugs Used for Treating Primary Aldosteronism Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 283. Japan Drugs Used for Treating Primary Aldosteronism Market Size, by Extended Release, 2017-2032 (USD Million)
TABLE 284. Japan Drugs Used for Treating Primary Aldosteronism Market Size, by Immediate Release, 2017-2032 (USD Million)
TABLE 285. Japan Drugs Used for Treating Primary Aldosteronism Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 286. Japan Drugs Used for Treating Primary Aldosteronism Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 287. Australia Drugs Used for Treating Primary Aldosteronism Market Size, 2017-2032 (USD Million)
TABLE 288. Australia Drugs Used for Treating Primary Aldosteronism Market Size, by Molecule, 2017-2032 (USD Million)
TABLE 289. Australia Drugs Used for Treating Primary Aldosteronism Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 290. Australia Drugs Used for Treating Primary Aldosteronism Market Size, by Line Of Therap

Companies Mentioned

  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Limited
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Related Topics

Related Reports

Elagolix Drugs Market - Global Forecast 2026-2032 - Product Image

Elagolix Drugs Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Ghrelin Market - Global Forecast 2026-2032 - Product Image

Ghrelin Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Diabetic Nephropathy - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Diabetic Nephropathy - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Somatostatin Analogs - Global Strategic Business Report - Product Image

Somatostatin Analogs - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
Desmopressin - Global Strategic Business Report - Product Image

Desmopressin - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.